Laurus Labs – Strong Q1 Splash, Pullback Underway

is currently trading around ₹838, down ~0.25% today, following a powerful Q1 FY26 financial performance. While the broader uptrend remains intact, recent profit-taking has softened the momentum—potentially setting up for the next leg higher Technical Snapshot Price is pulling back but holding above key short-term EMAs (10 & 20), maintaining structural support. RSI has eased toward mid-50s, signaling reduced overbought pressure while maintaining bullish tone. Volume today is below average, indicating calmer profit-booking, not panic selling. ** Short-Term Target**: ₹880–₹900 ** Support Zone**: ₹810–₹820 Fundamental Highlights FY25 vs FY24 (Annual) Revenue: ₹5,554 Cr (+10% YoY) EBITDA: ₹1,115 Cr (+40% YoY) → Margin ~20.1% Q1 FY26 (YoY Growth) Revenue: ₹1,570 Cr (+31%) EBITDA: ₹389 Cr (+127%) → Margin ~24.8% Net Profit (PAT): ₹162–163 Cr (robust ~1,150% YoY surge) Growth Drivers Strong execution in high-margin CDMO projects; over ₹493 Cr revenue from CDMO in Q1, up ~130% YoY. EBITDA margin expansion reflects better product mix and operating leverage. New capacity additions in gene & ADC and microbial fermentation facilities set stage for medium-term volume growth. Risks & Considerations Current valuation remains steep (P/E ~89x) — premium hinges on continued margin performance and volume ramp-up. CDMO revenues may remain uneven quarter-to-quarter due to project delivery timing ** Long-Term Target**: ₹950–₹1,000 (12–15 months view) ** Bottom Line**: Laurus Labs is showing strong operational recovery and margin trajectory. The recent pullback looks like a healthy pause—monitor for a breakout above ₹880 with renewed volume for next leg up.